Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9056249 | 0.81 | NR2E1 (0.56) | NR2E1HPGDHSD17B10TP53KDM4E | |
| SCHEMBL2515919 | 0.81 | NR2E1 (0.67) | NR2E1HPGDHSD17B10TP53HTR2A | |
| SCHEMBL12128242 | 0.81 | HTR1D (0.44) | NR2E1HSD17B10MAPTHTR1DHTR1B | |
| SCHEMBL21088052 | 0.80 | HTR1B (0.43) | NR2E1HPGDHSD17B10KDM4EALDH1A1 | |
| SCHEMBL6609244 | 0.80 | NR2E1 (0.57) | NR2E1HPGDHSD17B10TP53KDM4E | |
| SCHEMBL23875668 | 0.79 | NR2E1 (0.65) | NR2E1HPGDHSD17B10TP53KDM4E | |
| SCHEMBL6612451 | 0.79 | NR2E1 (0.59) | NR2E1HPGDHSD17B10TP53KDM4E | |
| SCHEMBL21754250 | 0.78 | NR2E1 (0.67) | NR2E1HPGDHSD17B10TP53KDM4E | |
| SCHEMBL4288282 | 0.78 | NR2E1 (0.67) | NR2E1HPGDHSD17B10TP53KDM4E | |
| SCHEMBL21900686 | 0.78 | NR2E1 (0.67) | NR2E1HPGDHSD17B10TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558446-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2019-06-12 | — | — | EP | disclosed |
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE SA (CH) | 2016-06-09 | — | — | US | disclosed |
| US-9221812-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2015-12-29 | — | — | US | disclosed |
| US-20110280808-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE, S.A. (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110280808-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE, S.A. (CH) | 2011-11-17 | — | — | US | disclosed |
| WO-2011128455-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE S.A. (CH) | 2011-10-20 | — | — | WO | disclosed |
| EP-0731092-B1 | Process for producing substituted 1,2,3,4-tetrahydrocarbazoles | BAYER AG (DE) | 1998-05-06 | — | — | EP | disclosed |
| US-5648500-A | Process for the preparation of substituted 1,2,3,4-tetrahydrocarbazoles | BAYER AKTIENGESELLSCHAFT (DE) | 1997-07-15 | — | — | US | disclosed |
| EP-0731092-A1 | Process for producing substituted 1,2,3,4-tetrahydrocarbazoles | BAYER AG (DE) | 1996-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280808-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | APP, PSEN1, PSEN2 | NR2E1 1300/4885HPGD 2612/4885HSD17B10 2994/4885 |
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | APP, PSEN1, PSEN2 | NR2E1 1300/4885HPGD 2612/4885HSD17B10 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.